Global Discovery To Development Innovation Forum 2017

Meaning

The 11th Annual Global Discovery To Development Innovation Forum (GDDIF) is the leading pharmaceutical R&D Summit for pharma decision makers, scientific leaders, and solutions experts.
This series brings together prominent leaders from both industry and academia to mindshare, benchmark and exchange cutting-edge innovation to manage, strategize and integrate new paradigms to surpass and transcend the quality of drug discovery, biology, and development.
Taking a truly integrated approach to drug discovery. The 10th Annual GDDIF is dedicated to scientific insights, technology innovation & strategy across areas such as medicinal chemistry, in vitro and in vivo biology, structural biology, and computer-aided drug design etc.

Themes

Innovation within Screening, Enabling Technologies and Collaborative Partnerships.
CRISPR-Cas and iPSC technologies for drug discovery.
How PBPK modelling has evolved in the last decade
PK-PD strategies implemented in early drug discovery
How physical properties influence ADME-Tox compound progression
The use of in-house ADME prediction tools in design
Physiologically based pharmacokinetic modelling
Understanding how to use in vitro data
Single Cell Analysis.
Small Molecule Medicinal Chemistry: Strategies and Technologies
Enabling Collaborative Data Analysis
Improving R&D Productivity & Data Quality
Open-Access Collaboration in Accelerating Early Stage Drug Discovery
How to Attract Potential Licensing Partners in Early Drug Discovery
soloMER™ Biologics: Next-Generation Therapeutics for the Site-Specific Treatment of Inflammatory Disease
Overcoming limitations of antibodies using engineered Affimer binding proteins

Testimonials

Client Testimonials

In addition to the excellent networking opportunities, and inspirational speakers, this year GDDIF was a great motivational event. We were inspired to take a step back and acknowledge the positives, and negatives, of open innovation. This is a very exciting time as technology can and is being used more and more in the world of clinical trials and mobile applications are now recognised as medical devices. Following a unique opportunity to interact with extraordinary leaders from around the globe, I left feeling excited as we open a new chapter of opportunities using technology in areas we have yet to dream of. Use of the technology will enable us to be more focussed and productive so we can deliver more for less cost.
- ESMS Global Ltd

Audience

Join Up To 150 Leaders & Attend The Exclusive GDDIF - The Original Innovation Summit. Job Titles Will Include

SVP R&D
Heads Of R&D

Informatics
Medicinal Chemistry
Heads of ADME & DMPK
Heads Of Discovery
Principal Scientists
Head Of External Collaborations
Heads of Toxicology
Lab Managers
Heads Of Pre Clinical
Personalised Medicine

Stream Talks

Strategies for Developing 3D Cell Culture Assays
Screening Natural Product-Based Compounds for Efficient Drug Discovery
Insight into The New Era of Structure-Based Drug Design GPCRs
Integrated Innovation in medicinal chemistry: what are the new technologies?

Innovation in Medicinal Chemistry: what are the new technologies?

Culture Assays for Use in Drug Discovery

Target Deconvolution Strategies in Novel Natural Compounds, Phenotypic Screening, Combined Screening

Evolution of Advance Natural Compounds and Potent Innovation in ADC’s

Sourcing and Designing More Physiologically.
The role of Open Innovation for Therapeutic Medicines

The latest in big R&D data solutions Novel therapies in companion diagnostics

Relevant Cellular Assays for Implementation in HTS Programmes

Overcoming Patient Variability | App of Genome Editing

Image Analysis and Data Collection, Literature Storage and Interpretation

Open-Access Collaboration in Accelerating Early Stage Drug Discovery

Thank you very much for giving me the opportunity to experience an exciting GDDIF. The fruitful interactions with technology experts, company executives and pharma researchers at the GDDIF already triggered follow up activities.
- Novartis Institutes for BioMedical Research